Skip to content
  • Home
  • About
  • Portfolio
  • Contact Us
Menu
  • Home
  • About
  • Portfolio
  • Contact Us

Portfolio/ Pharma Two B

Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. The company focuses on Fixed-Dose-combinations of two or more drugs with complementary and synergistic effects, providing high clinical value and shorter regulatory pathways (US 505(b)(2) approach). The company develops products in two therapeutic areas with great unmet needs, Parkinson’s disease and Cancer.

The Company’s leading product, P2B001 was successfully tested in a phase IIb clinical study with 149 parkinson’s disease patients in the US and Israel. The results showed a significant effect of improvement in the subjects condition according to several Parkinson’s disease scales compared to Placebo.

Pharma Two B main investors include Crossroad and JK&B.

www.pharma2b.com

Pharma2b

First Patients Dosed in Phase III Multi-center, Multinational Study to...

Based on positive data from a Phase IIb pivotal study suggesting that P2B001 may offer effective therapy with minimal side...
Pharma2b

Pharma Two B Ltd. Closes $30 Million Financing Round

REHOVOTH, Israel, February 27, 2017 — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for...

Contact us

Contact us for any questions and we will get back to you as soon as possible

2019 Crossroad Fund | BIT Enterprises Ltd.